2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis - Archive ouverte HAL
Article Dans Une Revue Arthritis & rheumatology Année : 2021

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Liana Fraenkel
Joan Bathon
  • Fonction : Auteur
Bryant England
E. William St.Clair
  • Fonction : Auteur
Thurayya Arayssi
  • Fonction : Auteur
Kristine Carandang
Kevin Deane
Mark Genovese
Kent Kwas Huston
  • Fonction : Auteur
Gail Kerr
  • Fonction : Auteur
Joel Kremer
Mary Nakamura
  • Fonction : Auteur
Linda Russell
  • Fonction : Auteur
Jasvinder Singh
Benjamin Smith
Jeffrey Sparks
Shilpa Venkatachalam
  • Fonction : Auteur
Mounir Al-Gibbawi
  • Fonction : Auteur
Joshua Baker
Kamil Barbour
Jennifer Barton
  • Fonction : Auteur
Laura Cappelli
Fatimah Chamseddine
  • Fonction : Auteur
Michael George
Sindhu Johnson
Lara Kahale
  • Fonction : Auteur
Basil Karam
  • Fonction : Auteur
Assem Khamis
Iris Navarro-Millán
Reza Mirza
  • Fonction : Auteur
Pascale Schwab
  • Fonction : Auteur
Namrata Singh
  • Fonction : Auteur
Marat Turgunbaev
  • Fonction : Auteur
Amy Turner
Sally Yaacoub
Elie Akl
  • Fonction : Auteur

Résumé

Objective To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. Methods We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. Results The guideline addresses treatment with disease‐modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high‐risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional). Conclusion This clinical practice guideline is intended to serve as a tool to support clinician and patient decision‐making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision‐making process based on patients’ values, goals, preferences, and comorbidities.

Dates et versions

hal-04207441 , version 1 (14-09-2023)

Identifiants

Citer

Liana Fraenkel, Joan Bathon, Bryant England, E. William St.Clair, Thurayya Arayssi, et al.. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & rheumatology, 2021, 73 (7), pp.1108-1123. ⟨10.1002/art.41752⟩. ⟨hal-04207441⟩
23 Consultations
0 Téléchargements

Altmetric

Partager

More